Linda Pullan

Dr. Pullan has been providing biotech and pharmaceutical companies solutions in identification, evaluation, valuation, negotiation and strategy for partnering in or out. She has an extensive deal sheet ranging from company acquisitions to Phase III compounds and from preclinical candidates to technologies with upfronts ranging from $10K to $100M. She also served as President and CEO of Viriome, Inc. and on the board of directors of Paloma Pharmaceuticals, Inc. Dr. Pullan has more than 20 years of drug industry experience, beginning in drug discovery at Monsanto/Searle/now Pfizer and ICI/Zeneca/now AstraZeneca. She contributed to and led teams that put AstraZeneca’s multi-billion dollar antipsychotic Seroquel® and other molecules into development. Her business development experiences began with in-licensing technology and early drug candidates in all therapeutic areas at what is now AstraZeneca, and continued as head of oncology and hematology licensing for Amgen. Dr. PUllan then joined Kosan Biosciences as VP of Business Development and experienced all the tasks of out-licensing and business development in a small company. She has a Ph.D. in Biochemistry from UC Riverside and a B.S. in Chemistry from University of Utah.